Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial

Schizophrenia Research
Antony LoebelSteven G Potkin


This study was designed to evaluate the short-term efficacy and safety of once-daily lurasidone (80 mg/day and 160 mg/day) in the treatment of an acute exacerbation of schizophrenia. Participants, who were recently admitted inpatients with schizophrenia with an acute exacerbation of psychotic symptoms, were randomly assigned to 6 weeks of fixed-dose, double-blind treatment with lurasidone 80 mg (n=125), lurasidone 160 mg (n=121), quetiapine XR 600 mg (QXR-600 mg; n=119; active control included to test for assay sensitivity), or placebo (n=121), all dosed once daily in the evening. Efficacy was evaluated using a mixed-model repeated-measures analysis of the change from Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) total score (the primary efficacy measure) and Clinical Global Impressions severity (CGI-S) score (the key secondary efficacy measure). Treatment with both doses of lurasidone or with QXR-600 mg was associated with significantly greater improvement at Week 6 on PANSS total score, PANSS positive and negative subscale scores, and CGI-S score compared with placebo. The endpoint responder rate (≥ 20% improvement in PANSS total score) was higher in subjects treated with lurasidone 80 mg (65%; p<0.001), ...Continue Reading


Aug 20, 2014·The Medical Clinics of North America·Carolyn J Brenner, Stanley I Shyn
Jan 31, 2015·Expert Opinion on Investigational Drugs·Mauro Giovanni CartaJoseph R Calabrese
Nov 18, 2014·Expert Opinion on Drug Safety·Richard MusilMichael Hamerle
Jun 27, 2015·Expert Opinion on Pharmacotherapy·Dawn BruijnzeelRajiv Tandon
Sep 17, 2013·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Philip D HarveyAntony Loebel
Oct 5, 2014·European Psychiatry : the Journal of the Association of European Psychiatrists·Antony LoebelS R Marder
May 21, 2016·Pharmacological Reports : PR·Rafał R JaeschkeWojciech Datka
Jun 28, 2016·Expert Opinion on Drug Safety·L OrsoliniD De Berardis
Feb 5, 2014·Schizophrenia Bulletin·Stefan LeuchtJohn M Davis
Mar 8, 2017·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Michael OstacherAntony Loebel
Jul 8, 2017·Expert Opinion on Investigational Drugs·Lynn McClellanCraig A Erickson
Jun 14, 2017·Statistics in Medicine·Tobias Mütze, Tim Friede
Feb 3, 2016·Therapeutic Advances in Psychopharmacology·Steven G PotkinJohn Guarino
Apr 27, 2018·Journal of Comparative Effectiveness Research·Daisy Ng-MakAntony Loebel
May 12, 2018·The Cochrane Database of Systematic Reviews·Myrto T SamaraStefan Leucht
Apr 14, 2016·PharmacoEconomics·Krithika RajagopalanAntony Loebel
Sep 14, 2017·Expert Opinion on Drug Safety·Maurizio PompiliPaolo Girardi
Jan 24, 2018·Journal of Intensive Care Medicine·Marlena A FoxCharles Hunley
Dec 15, 2019·Asia-Pacific Psychiatry : Official Journal of the Pacific Rim College of Psychiatrists·Teruhiko HiguchiKatsuhiko Hagi
Dec 17, 2019·The American Journal of Psychiatry·Stefan LeuchtJohn M Davis
Apr 26, 2020·Journal of Clinical Psychopharmacology·Herbert Y MeltzerMyung A Lee
Apr 29, 2020·Pharmacotherapy·Constance L ChowAmy M VandenBerg
Jul 22, 2015·International Clinical Psychopharmacology·Jonathan M MeyerAntony Loebel
Jul 31, 2020·Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·S K ZyryanovE S Mosolova
Dec 10, 2016·Evidence-based Mental Health·Simon Wandel, Satrajit Roychoudhury
May 6, 2017·Journal of Child and Adolescent Psychopharmacology·Robert GoldmanRobert L Findling


Apr 1, 1979·The British Journal of Psychiatry : the Journal of Mental Science·S A Montgomery, M Asberg
May 1, 1989·The British Journal of Psychiatry : the Journal of Mental Science·T R Barnes
Jan 1, 1987·Schizophrenia Bulletin·S R KayL A Opler
Jan 1, 1970·Acta Psychiatrica Scandinavica. Supplementum·G M Simpson, J W Angus
Jul 1, 1993·Journal of Psychiatric Research·B N AxelrodL D Alphs
Feb 3, 1999·International Journal for Quality in Health Care : Journal of the International Society for Quality in Health Care·R M KaplanJ P Anderson
Sep 9, 2000·Schizophrenia Research·U OsbyP Sparén
Mar 12, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Wesley K KroezeBryan L Roth
Jun 30, 2004·CNS Drugs·Bruce J KinonPeter F Buckley
Jul 14, 2005·Journal of Clinical Psychopharmacology·Leslie CitromeJerome Levine
Dec 25, 2008·Schizophrenia Research·Leslie CitromeKafi N Sanders
Feb 24, 2009·NeuroImage·Ana M CatafauBarcelona Clinical Imaging in Psychiatry Group
Mar 27, 2009·CNS Drugs·Claudine M Baldwin, Lesley J Scott
Dec 28, 2010·Trends in Molecular Medicine·Christoph U CorrellAnil K Malhotra
Mar 16, 2011·CNS Neuroscience & Therapeutics·Thomas L Schwartz, Stephen M Stahl
Jun 17, 2011·The American Journal of Psychiatry·Herbert Y MeltzerAntony Loebel
Oct 20, 2011·Nature Reviews. Endocrinology·Marc De HertChristoph U Correll
Aug 21, 2012·Psychopharmacology·Masaaki OgasaJohn Guarino

Related Concepts

Glycated Hemoglobin TEST
Metabolic Process, Cellular
Antipsychotic Effect
Receptors, Histamine H1
Laboratory Procedures
Low Density Lipoprotein Cholesterol Measurement

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.